BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 21557977)

  • 41. A novel design of targeted endocrine and cytokine therapy for breast cancer.
    Zhang G; Li W; Holle L; Chen N; Chen WY
    Clin Cancer Res; 2002 Apr; 8(4):1196-205. PubMed ID: 11948133
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
    Tan G; Wang ZY; Yin S
    Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
    Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H
    J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo.
    Yan X; Doffek K; Yin C; Krein M; Phillips M; Sugg SL; Johnson B; Shilyansky J
    Cancer Immunol Immunother; 2012 Nov; 61(11):1917-27. PubMed ID: 22476407
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals.
    Coveney E; Clary B; Iacobucci M; Philip R; Lyerly K
    Surgery; 1996 Aug; 120(2):265-72; discussion 272-3. PubMed ID: 8751592
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition.
    Sultan H; Kumai T; Fesenkova VI; Fan AE; Wu J; Cho HI; Kobayashi H; Harabuchi Y; Celis E
    Cancer Immunol Res; 2018 May; 6(5):617-627. PubMed ID: 29483127
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.
    Mkrtichyan M; Ghochikyan A; Loukinov D; Davtyan H; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG
    Gene Ther; 2008 Jan; 15(1):61-4. PubMed ID: 17972923
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Delivery of IL-2 to the T Cell Surface Through Phosphatidylserine Permits Robust Expansion of CD8 T Cells.
    MacDonald A; Lam B; Lin J; Ferrall L; Kung YJ; Tsai YC; Wu TC; Hung CF
    Front Immunol; 2021; 12():755995. PubMed ID: 34804041
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S.
    Abe H; Wada H; Baghdadi M; Nakanishi S; Usui Y; Tsuchikawa T; Shichinohe T; Hirano S; Seino K
    Hum Cell; 2016 Apr; 29(2):58-66. PubMed ID: 26857856
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Transfer of the IL-37b gene elicits anti-tumor responses in mice bearing 4T1 breast cancer.
    Wang WQ; Zhao D; Zhou YS; Hu XY; Sun ZN; Yu G; Wu WT; Chen S; Kuang JL; Xu GG; Han ZC; Wang BM; Yang JX; Feng XM
    Acta Pharmacol Sin; 2015 Apr; 36(4):528-34. PubMed ID: 25832432
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The antitumor immunopreventive effects of a DNA vaccine against CYP26a1 on mouse breast carcinoma.
    Wang RC; Liu ZK; Chen W; Yang Y; Peng JP
    Vaccine; 2011 Nov; 29(48):8915-23. PubMed ID: 21959331
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model.
    Urueña C; Gomez A; Sandoval T; Hernandez J; Li S; Barreto A; Fiorentino S
    Integr Cancer Ther; 2015 Sep; 14(5):468-83. PubMed ID: 26220604
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modeling and integral X-ray, optical, and MRI visualization of multiorgan metastases of orthotopic 4T1 breast carcinoma in BALB/c mice.
    Baklaushev VP; Grinenko NF; Yusubalieva GM; Abakumov MA; Gubskii IL; Cherepanov SA; Kashparov IA; Burenkov MS; Rabinovich EZ; Ivanova NV; Antonova OM; Chekhonin VP
    Bull Exp Biol Med; 2015 Feb; 158(4):581-8. PubMed ID: 25705045
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective immune response against P32 oncogenic peptide-pulsed PBMCs in mouse models of breast cancer.
    Dehghan-Manshadi M; Nikpoor AR; Hadinedoushan H; Zare F; Sankian M; Fesahat F; Rafatpanah H
    Int Immunopharmacol; 2021 Apr; 93():107414. PubMed ID: 33578183
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Perioperative immunomodulation with Flt3 kinase ligand or a whole tumor cell vaccine is associated with a reduction in lung metastasis formation after laparotomy in mice.
    Carter JJ; Feingold DL; Oh A; Kirman I; Wildbrett P; Stapleton G; Asi Z; Fowler R; Bhagat G; Huang EH; Fine RL; Whelan RL
    Surg Innov; 2006 Mar; 13(1):41-7. PubMed ID: 16708154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of lipid-phosphatidylserine (PS) as the target of unbiasedly selected cancer specific peptide-peptoid hybrid PPS1.
    Desai TJ; Toombs JE; Minna JD; Brekken RA; Udugamasooriya DG
    Oncotarget; 2016 May; 7(21):30678-90. PubMed ID: 27120792
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction of an Ultraviolet C-Irradiated 4T1 Murine Breast Cancer Whole-Cell Vaccine Model.
    Szebeni GJ; Alföldi R; Nagy LI; Neuperger P; Gémes N; Balog JÁ; Tiszlavicz L; Puskás LG
    Vaccines (Basel); 2023 Jul; 11(7):. PubMed ID: 37515069
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Addition of interleukin-12 to GA733 tumor protein vaccine leads to development of tumor protective immunity despite surgical stress.
    Kirman I; Poltoratskaia N; Herlyn D; Whelan RL
    Surg Endosc; 2003 Jul; 17(7):1135-9. PubMed ID: 12658425
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination immunotherapy with extract of heated 4T1 and naloxone in mouse model of breast cancer.
    Jahangiri S; Abtahi Froushani SM; Delirezh N
    Turk J Med Sci; 2016 Feb; 46(2):518-23. PubMed ID: 27511520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phosphatidylserine counteracts physiological and pharmacological suppression of humoral immune response.
    Guarcello V; Triolo G; Cioni M; Morale MC; Farinella Z; Scapagnini U; Marchetti B
    Immunopharmacology; 1990; 19(3):185-95. PubMed ID: 2394581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.